<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343231">
  <stage>Registered</stage>
  <submitdate>22/07/2011</submitdate>
  <approvaldate>22/07/2011</approvaldate>
  <actrnumber>ACTRN12611000774921</actrnumber>
  <trial_identification>
    <studytitle>Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial</studytitle>
    <scientifictitle>An Australasian-lead, investigator-initiated, prospective, parallel group, double-blind, placebo-controlled, multi-centre, randomised, controlled trial to establish the effect(s) of routine administration of fluoxetine (20mg once daily) in patients with recent stroke.</scientifictitle>
    <utrn />
    <trialacronym>AFFINITY</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Fluoxetine (20mg once daily) for 6 months via oral capsule or enteral tube.</interventions>
    <comparator>Placebo capsule taken once daily for 6 months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>modified Rankin scale</outcome>
      <timepoint>Baseline, 1 month, 3 months, 6 months, 12 months  </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>depression (PHQ-9)</outcome>
      <timepoint>Baseline, 1 month, 3 months, 6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>overall health status (Stoke Impact Scale)</outcome>
      <timepoint>6 months, 12 months </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cognition (TICSm)</outcome>
      <timepoint>6 months, 12 months  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>health related quality of life (EQ-5D-5L)</outcome>
      <timepoint>6 months, 12 months </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>social functioning (FAI)</outcome>
      <timepoint>Baseline, 6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>fatigue (vitality of subscale of SF36)</outcome>
      <timepoint>6 months, 12 months  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>health care utilisation (Data linkage to patient medical records and patient diary recording hospital admissions/ visits &amp; GP/specialist visits)</outcome>
      <timepoint>6 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adherence to trial medication (patient self report of medication compliance &amp; tablet counting)</outcome>
      <timepoint>1 month, 3 months, 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men or women aged 18 years or more with: - Clinical diagnosis of stroke 2-15 days previously (Day of stroke onset = Day 0, randomise on Day 2-15); - Brain imaging consistent with ischaemic or haemorrhagic (intracerebral and/or subarachnoid) stroke (including normal CT brain scan); - Persisting measurable focal neurological deficits (e.g. motor, somatosensory, visual, language, cognitive) present at randomisation and severe enough to warrant treatment from the perspective of patient or carer(s). </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded if: - under 18 yr old; - history of epileptic seizures; - history of bipolar disorder; - history of drug overdose or attempted suicide; - Allergy or contra indication to fluoxetine including hepatic failure (ALT &gt; 120 U/l ), renal impairment (creatinine &gt; 180 micromol/l), hyponatremia (sodium &lt; 125mmol/L); - current or recent (&lt;1 month) depression requiring treatment with a selective serotonin reuptake inhibitor (SSRI) antidepressant; - use of a monoamine oxidase inhibitor (MAOI) in last 5 weeks; -  current treatment with Pimozide; - current treatment with other antidepressnts, unless use in conjuction with fluoxetine is acceptable (i.e. mirtazepine, trazadone, tricyclic antidepressant) or the patient agrees to discontinue and this is medically appropriate; - current treatment with tramadol, unless patient agrees to discontinue use; - current treatment with a antipsychotic drug (neuroleptic); - not available for follow up for the next 365 days e.g. no fixed home address; - life-threatening illness (e.g. advanced cancer) other than stroke likely to reduce 365 day survival; - pregnant, breast-feeding or of child-bearing age and not taking contraception (a minimum contraceptive measure is an oral contraceptive); - enrolled in another interventional clinical research trial. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/09/2012</anticipatedstartdate>
    <actualstartdate>11/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,SA,WA,VIC</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Swan Districts Hospital - Middle Swan</hospital>
    <hospital>Osborne Park Hospital - Stirling</hospital>
    <hospital>Rockingham General Hospital - Cooloongup</hospital>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>Western Hospital - Footscray</hospital>
    <hospital>Blacktown Hospital - Blacktown</hospital>
    <hospital>Campbelltown Hospital - Campbelltown</hospital>
    <hospital>Camden Hospital - Camden</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Hornsby Ku-ring-gai Hospital - Hornsby</hospital>
    <hospital>Wagga Wagga Base Hospital - Wagga Wagga</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Island </state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>Wellington Street
Perth, Western Australia
6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>The George Institute for Global Health</sponsorname>
      <sponsoraddress>PO Box M201 
Missenden Road NSW 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Does routine administration of fluoxetine (20mg od) in the 6 months after acute stroke improve patients functional outcome?</summary>
    <trialwebsite>www.affinitytrial.org</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HREC Royal Perth Hospital</ethicname>
      <ethicaddress>Level 5 Colonial House Royal Perth Hospital</ethicaddress>
      <ethicapprovaldate>24/02/2012</ethicapprovaldate>
      <hrec>2011/131</hrec>
      <ethicsubmitdate>31/08/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Sydney Local Health District </ethicname>
      <ethicaddress>Room 1072, Education Block, Westmead Hospital, Hawkesbury Road, Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>30/04/2013</ethicapprovaldate>
      <hrec>HREC2013/3/4.1(3619)AU RED HREC/13/WMEAD/165</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Graeme Hankey </name>
      <address>School of Medicine and Pharmacology (SCGH Unit M503) 
Harry Perkins Institute of Medical Research
2nd Floor, QQ Block QEII Medical Centre 
6 Verdun Street Nedlands WA 6009 </address>
      <phone>+61 8 6151 1061</phone>
      <fax />
      <email>graeme.hankey@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sarah Claxton</name>
      <address>Stroke Research 
School of Medicine and Pharmacology (SCGH Unit M503) 
Harry Perkins Institute of Medical Research
2nd Floor Rm 234, QQ Block QEII Medical Centre 
6 Verdun Street Nedlands WA 6009 </address>
      <phone>+61 8 6151 1061</phone>
      <fax />
      <email>sarah.claxton@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Hankey</name>
      <address>School of Medicine and Pharmacology (SCGH Unit M503) 
Harry Perkins Institute of Medical Research
2nd Floor, QQ Block QEII Medical Centre 
6 Verdun Street Nedlands WA 6009 </address>
      <phone>+61 8 6151 1061</phone>
      <fax />
      <email>graeme.hankey@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>